- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Alkermes Launches New Website Offering Education About Alcohol Dependence
Dublin-headquarted biopharma Alkermes has launched a new website to offer education about alcohol dependence. Myrelationshipwithalcohol.com offers educational information about alcohol dependence, an interactive questionnaire developed by the National Institutes of Health (NIH) designed to assess personal drinking patterns, and a discussion guide to help start a conversation with healthcare providers about the disease and treatment options.
"As one of the few companies working in this disease area, we felt compelled to develop a resource to help people better understand alcohol dependence," commented Blair Jackson, Executive Vice President, Chief Operating Officer of Alkermes. ”Despite its prevalence, understanding of the disease itself and awareness of approved treatment options that exist remain low. Our aim is to provide people who may be living with the disease, or those who are caring for people living with it, with information to help empower them to speak with a healthcare provider.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
